Tulasee Bio-Eth. (524514)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Price is near its 52-week low of ₹17.32, so much of the speculative premium has been stripped out.
• Small market cap of ₹11 crore means a modest operational recovery could move per-share numbers sharply.
• Latest quarter's net loss is only -₹0 crore, suggesting current cash burn is not extreme.
• Commodity chemicals is a cyclical industry, so a future upturn in realisations could provide an operating lever.

Concerns

• Zero revenue and zero profit in the latest quarter mean there is no business currently being run.
• ROE of -24.60% and ROCE of -1.61% show capital is being eroded, not compounded.
• P/B of 13.13 against book value of ₹1.35 provides no margin of safety; you are paying a huge premium for a loss-making shell.
• Piotroski F-Score of 2/9 and missing promoter holding/debt data make financial health impossible to trust.

AI Analysis

Let me start with the simple truth: I cannot value a business that has no sales. Tulasee Bio-Eth's latest quarter shows revenue of ₹0 crore and net profit of ₹0 crore. With a Piotroski F-Score of 2/9, the fundamentals are weak. Graham taught me to buy with a margin of safety, not hope. At ₹17.73, the market cap is ₹11 crore, but book value per share is only ₹1.35 – so I am paying 13.13 times book for a commodity chemical company that is destroying value. ROE is -24.60% and ROCE is -1.61%; this is a capital destroyer, not a compounder. There is no dividend, no demonstrated growth, and profit growth has collapsed by 100%. The price has fallen from ₹71.21 to ₹17.73, which might look like opportunity, but a falling stock is not the same as an undervalued business. Mr. Market is depressed, and maybe he will offer lower prices. But I need the business to survive and eventually earn. With book value of only ₹1.35 per share, the current price already capitalizes a huge recovery. If sales don't restart, equity can keep eroding. The lack of promoter holding data and a debt/equity figure of N/A mean I cannot assess whether insiders share my pain or whether hidden liabilities exist. This is a speculative instrument, not an investment. If forced to file it, I would call it a turnaround candidate – but only in the sense that it needs a complete operational rebirth. I watch from the sidelines until actual revenue returns and the balance sheet becomes clean.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer